The study, which was published in the May 2013 issue of Molecular Therapy-Nucleic Acids, a companion journal to Molecular Therapy, evaluated the properties of renal cell carcinoma RNA after amplification and following introduction into dendritic cells using newly developed tests
In a six-patient trial assessing synergy between CRLX101 and Avastin in renal cell carcinoma, the drug combination was well tolerated without dose-limiting toxicities...Results of the pre-planned interim analysis showed that Lymphoseek met the primary efficacy endpoint of accurately identifying sentinel lymph nodes in subjects with squamous cell carcinoma of the head or in the mouth, as compared to the removal of all lymph nodes during multiple level nodal dissection surgery of the head and neck
single-arm Phase II trial (REO 021) of intravenous Reolysin in combination with carboplatin and paclitaxel met the primary statistical endpoint of objective tumor response rate in squamous cell carcinoma of the lung (SCCLC
Argos Therapeutics Inc., of Durham, N.C., said it validated the durability of the immune response for metastatic renal cell carcinoma patients treated with AGS-003
Argos Therapeutics Inc., of Durham, N.C., reported updated results from its Phase II study of AGS-003, its most advanced product candidate for the treatment of metastatic renal cell carcinoma (mRCC
Oncolytics Biotech Inc., of Calgary, Alberta, said that in a Phase II trial of Reolysin with carboplatin and paclitaxel in patients with squamous cell carcinoma of the lung, 95 percent of evaluable patients (19 out of 20) had overall tumor shrinkage
Acceleron Pharma Inc., of Cambridge, Mass., said it started a Phase II study testing dalantercept (ACE-041), an angiogenesis inhibitor designed to target the activin receptor-like kinase pathway, in combination with Inlyta (axitinib, Pfizer Inc.), a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with metastatic renal cell carcinoma
The Phase III trial of Lymphoseek (technetium Tc 99m tilmanocept) for injection, an intraoperative lymphatic mapping agent, is designed to demonstrate the performance of Lymphoseek in identifying sentinel lymph nodes in subjects with squamous cell carcinoma on the head or in the mouth
OncoSec Medical Inc., of San Diego, reported that ImmunoPulse, delivered by electroporation, may give increased levels of interleukin-12 in the microenvironment of tumors in Merkel cell carcinoma
OncoSec Medical Inc., of San Diego, reported interim results from a Phase IV trial of NeoPulse in skin cancer at the World Meeting of Interdisciplinary Melanoma and Skin Care Centres and EADO Congress in Barcelona, Spain, showing a complete response greater than 90 percent in basal cell carcinoma patients and 70 percent in squamous cell carcinoma patients at six months
Immatics biotechnologies GmbH, of Tuebingen, Germany, completed patient recruitment into the pivotal Phase III trial evaluating its lead cancer vaccine IMA901 for renal cell carcinoma (RCC
Pfizer Inc., of New York, said a Phase III study of Inlyta (axitinib) did not meet its primary endpoint of demonstrating statistically significantly longer progression-free survival (PFS) vs. Nexavar (sorafenib, Onyx Pharmaceuticals Inc. and Bayer AG) in treatment-naïve patients with advanced renal cell carcinoma
Oncolytics Biotech Inc., of Calgary, Alberta, reported preliminary results from a Phase II trial of Reolysin plus carboplatin and paclitaxel in patients with squamous cell carcinoma of the lung
Archexin, a potential first-in-class Akt protein kinase inhibitor, has orphan drug status for renal cell carcinoma, glioblastoma and pancreatic, stomach and ovarian cancers
OncoSec Medical Inc., of San Diego, said data from an interim analysis from two Phase III trials, HNBE-01 and HNBE-02, using electrochemotherapy to treat locally occurring recurrent and second primary squamous cell carcinoma of the head and neck (SCCHN) showed that OMS ElectoChemotherapy achieved the primary endpoint of preserving quality of life, compared to surgery
Argos Therapeutics Inc., of Durham, N.C., said it secured a special protocol assessment for a Phase III study of AGS-003 in metastatic renal cell carcinoma...The study, dubbed ADAPT (Autologous Dendritic Cell Immunothearpy [AGS-003] Plus Standard Treatment of Advanced Renal Cell Carcinoma), is expected to begin dosing patients in the second half of this year, with a primary endpoint of overall survival
The study, which was published in the May 2013 issue of Molecular Therapy-Nucleic Acids, a companion journal to Molecular Therapy, evaluated the properties of renal cell carcinoma RNA after amplification and following introduction into dendritic cells using newly developed tests